Aratana Therapeutics Quick Ratio (PETX) starting from the first quarter 2019 to first quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aratana Therapeutics, Inc.  (PETX)

Aratana Therapeutics's Quick Ratio

PETX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2019, Quick Ratio fell to 12.48 above Aratana Therapeutics, Inc. average.

Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Quick Ratio than Aratana Therapeutics in first quarter 2019. While Quick Ratio total ranking in the first quarter 2019 has deteriorated compared to the prior quarter from 93 to 291.

Explain Quick Ratio?
How much Cash & cash equivalents PETX´s has?
What are PETX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PETX Quick Ratio (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3		 (Jun 30 2018)
Q2		 (Mar 31 2018)
Q1
Y / Y Current Liabilities Change -86.51 % -96.64 % 19.09 % 37.9 % -7.1 %
Y / Y Cash & cash equivalent Change -44.63 % -36.89 % -20.36 % -25.25 % -1.61 %
Quick Ratio MRQ 12.48 46.84 2.41 2.67 3.04
PETX's Total Ranking # 291 # 93 # 987 # 289 # 245
Seq. Current Liabilities Change 225.91 % -96.08 % 3.39 % 2.12 % -18.77 %
Seq. Cash & cash equivalent Change -13.16 % -23.83 % -6.68 % -10.3 % -1.02 %



Quick Ratio first quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 104
Overall Market # 291


Quick Ratio Statistics
High Average Low
46.84 8.93 1.21
(Dec 31 2018)   (Sep 30 2013)




Financial Statements
Aratana Therapeutics's Current Liabilities $ 3 Millions Visit PETX's Balance sheet
Aratana Therapeutics's Cash & cash equivalent $ 37 Millions Visit PETX's Balance sheet
Source of PETX's Sales Visit PETX's Sales by Geography


Cumulative Aratana Therapeutics's Quick Ratio

PETX's Quick Ratio for the trailling 12 Months

PETX Quick Ratio

 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months		 (Jun 30 2018)
12 Months		 (Mar 31 2018)
12 Months
Y / Y Current Liabilities TTM Growth -41.6 % -20.74 % 8.77 % 11 % 6.29 %
Y / Y Cash & cash equivalent TTM Growth -31.35 % -21.18 % -18.37 % -21.85 % -22.54 %
Quick Ratio TTM 3.95 3.29 2.64 2.91 3.36
Total Ranking TTM # 4780 # 4793 # 4859 # 291 # 4817
Seq. Current Liabilities TTM Growth -27.74 % -27.61 % 4.09 % 7.27 % -1.94 %
Seq. Cash & cash equivalent TTM Growth -13.24 % -9.95 % -5.41 % -7.11 % -0.38 %

Quick ratio ranking by company, industry and sector >> Back to PETX Financial Strength Comparisons >> Go to Compare PETX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Aratana Therapeutics's average Cash & cash equivalent, this led to increase in in Aratana Therapeutics's Quick Ratio to 3.95, Quick Ratio remained below PETX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 452 other companies have achieved higher Quick Ratio than Aratana Therapeutics. While Quick Ratio overall ranking has improved so far to 4780, from total ranking during the twelve months ending fourth quarter 2018 at 4793.

Explain Quick Ratio?
How much Cash & cash equivalents PETX´s has?
What are PETX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 453
Healthcare Sector # 880
Within the Market # 4780


trailing twelve months Quick Ratio Statistics
High Average Low
10.84 5.23 2.17
(Mar 31 2015)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Mar 31 2019, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2019 MRQ Cash & cash equivalentMar 31 2019 MRQ Current Liabilities
Rhythm Pharmaceuticals Inc   31.90 $ 400.945  Millions$ 12.567  Millions
G1 Therapeutics Inc   30.11 $ 347.797  Millions$ 11.549  Millions
Genprex Inc   30.06 $ 6.946  Millions$ 0.231  Millions
Nexien Biopharma Inc   29.77 $ 0.235  Millions$ 0.008  Millions
Igc Pharma Inc   29.17 $ 25.610  Millions$ 0.878  Millions
Entasis Therapeutics Holdings Inc   28.55 $ 135.620  Millions$ 4.751  Millions
Prothena Corporation Public Limited Company  27.51 $ 410.106  Millions$ 14.906  Millions
Verrica Pharmaceuticals Inc   27.20 $ 83.282  Millions$ 3.062  Millions
Aurinia Pharmaceuticals Inc   27.09 $ 306.019  Millions$ 11.295  Millions
Turning Point Therapeutics Inc.  25.66 $ 90.084  Millions$ 3.511  Millions
Kiniksa Pharmaceuticals International Plc  25.34 $ 570.437  Millions$ 22.508  Millions
Nextcure Inc   24.79 $ 125.549  Millions$ 5.065  Millions
Gyre Therapeutics Inc   24.09 $ 105.277  Millions$ 4.370  Millions
Urogen Pharma Ltd   24.04 $ 247.099  Millions$ 10.277  Millions
Crescent Biopharma Inc   23.55 $ 195.613  Millions$ 8.307  Millions
Biospecifics Technologies Corp  22.55 $ 84.497  Millions$ 3.748  Millions
Synthorx, Inc.  21.99 $ 179.337  Millions$ 8.155  Millions
Neurogene Inc   21.84 $ 74.169  Millions$ 3.396  Millions
Kezar Life Sciences Inc   21.26 $ 101.134  Millions$ 4.758  Millions
Filana Therapeutics Inc   21.20 $ 19.125  Millions$ 0.902  Millions
Marker Therapeutics inc   20.97 $ 57.707  Millions$ 2.752  Millions
Phasebio Pharmaceuticals Inc.  20.92 $ 51.894  Millions$ 2.481  Millions
Allakos Inc   20.31 $ 167.188  Millions$ 8.232  Millions
Equillium Inc   20.19 $ 61.607  Millions$ 3.052  Millions
Arrowhead Pharmaceuticals Inc   19.98 $ 218.200  Millions$ 10.923  Millions
Sage Therapeutics Inc   19.76 $ 1,351.251  Millions$ 68.376  Millions
Ra Pharmaceuticals Inc   19.70 $ 191.647  Millions$ 9.728  Millions
Principia Biopharma Inc   19.32 $ 163.619  Millions$ 8.469  Millions
Achillion Pharmaceuticals Inc  19.28 $ 254.068  Millions$ 13.179  Millions
Lixte Biotechnology Holdings Inc   18.48 $ 3.894  Millions$ 0.211  Millions

Date modified: 2026-09-08T15:22:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.